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One sentence summary: Cellular and computational models and bronchial biopsies from 24 
asthma patients show that a DP2 antagonist reduces airway smooth muscle mass in asthma. 25 
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Abstract 26 
Increased airway smooth muscle mass, a feature of airway remodeling in asthma, is the 27 
strongest predictor of airflow limitation and contributes to asthma-associated morbidity and 28 
mortality. No current drug therapy for asthma is known to affect airway smooth muscle mass. 29 
Although there is increasing evidence that prostaglandin D2 type 2 receptor (DP2) is expressed 30 
in airway structural and inflammatory cells, few studies have addressed the expression and 31 
function of DP2 in airway smooth muscle cells. We report that the DP2 antagonist fevipiprant 32 
reduced airway smooth muscle mass in bronchial biopsies from patients with asthma who had 33 
participated in a previous randomized placebo-controlled trial. We developed a computational 34 
model to capture airway remodeling. Our model predicted that a reduction in airway 35 
eosinophilia alone was insufficient to explain the clinically observed decrease in airway smooth 36 
muscle mass without a concomitant reduction in the recruitment of airway smooth muscle cells 37 
or their precursors to airway smooth muscle bundles that comprise the airway smooth muscle 38 
layer. We experimentally confirmed that airway smooth muscle migration could be inhibited 39 
in vitro using DP2-specific antagonists in an airway smooth muscle cell culture model. Our 40 
analyses suggest that fevipiprant, through antagonism of DP2, reduced airway smooth muscle 41 
mass in patients with asthma by decreasing airway eosinophilia in concert with reduced 42 
recruitment of myofibroblasts and fibrocytes to the airway smooth muscle bundle. Fevipiprant 43 
may thus represent a potential therapy to ameliorate airway remodeling in asthma.     44 
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Introduction 45 
Asthma affects over 300 million people worldwide and its prevalence is increasing (1) despite 46 
currently available therapies (2). Asthma is characterised by variable airflow limitation that 47 
becomes more persistent in severe disease. Increased airway smooth muscle (ASM) mass is an 48 
important component of airway remodeling in asthma, contributing substantially to symptoms 49 
and disordered airway physiology (3-5). To date, no drug has impacted upon the increased 50 
ASM mass observed in asthma in randomized placebo-controlled trials (3, 4). However, 51 
bronchial thermoplasty has demonstrated a potential reduction in ASM mass in asthma in 52 
uncontrolled studies (6-7).  53 
 54 
The prostaglandin (PG) D2 type 2 receptor (DP2, also known as chemoattractant receptor-55 
homologous molecule expressed on T helper [Th] 2 cells [CRTh2]) is expressed by 56 
inflammatory cells critical in the immunopathogenesis of asthma, including eosinophils, Th2 57 
lymphocytes, type 2 innate lymphoid cells, and mast cells. DP2 activation promotes cellular 58 
release of cytokines, inflammatory cell migration, and cell survival (8-10). Its archetypal ligand 59 
PGD2 is predominantly released by mast cells localized to the ASM-bundle (11). The DP2 60 
antagonist fevipiprant has been shown to improve asthma symptoms, lung function, airway 61 
eosinophilia, and epithelial integrity (4). However, the role of the PGD2/DP2 axis in ASM 62 
dysfunction in asthma has not been extensively studied. We hypothesized that the PGD2/DP2 63 
axis may contribute to increased ASM mass in asthma, and that antagonism of DP2 with 64 
fevipiprant might result in a decrease in ASM mass.  65 
 66 
Here, we analysed bronchial biopsies from asthma patients treated with the DP2 antagonist 67 
fevipiprant in a previous phase 2a randomized, placebo-controlled trial undertaken to 68 
determine the impact of drug upon airway inflammation, remodeling and asthma control (4). 69 
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Using an agent-based computational model representing an asthmatic airway in human patients 70 
and supported by in vitro ASM cell-based observations, we propose that the reduced ASM 71 
mass observed in the bronchial biopsies after fevipiprant treatment may be a consequence of 72 
inhibition of eosinophilic airway inflammation together with reduced recruitment of 73 
myofibroblasts and fibrocytes to the ASM bundle.  74 
 75 
Results 76 
Fevipiprant reduces ASM mass in subjects with asthma in a randomized placebo-77 
controlled trial 78 
We obtained bronchial biopsies from moderate-to-severe asthmatics with airway eosinophilic 79 
inflammation, as evidenced by increased sputum eosinophil counts. These individuals had 80 
participated in a 12-week single-centre (University of Leicester), randomized, double-blind, 81 
parallel-group, placebo-controlled trial of the DP2 antagonist fevipiprant (4). We then 82 
performed an a priori quantification of ASM mass (percentage of total bronchial biopsy area) 83 
(11).  A representative photomicrograph of a bronchial biopsy from a subject showing 84 
disrupted epithelium and increased ASM mass is shown in Fig. 1A. The absolute ASM mass 85 
percentage (mean ± standard error of the mean [SEM]) observed decreased significantly 86 
following treatment with fevipiprant (-13 ± 5%; p=0.022, n=14) versus placebo (4 ± 5%; 87 
p=0.52, n=13) (mean difference [95% confidence interval (CI)] -16.2 [-1.4 to -31.1] %; 88 
p=0.034) (Fig. 1B).  In view of the above data, we performed a post hoc quantification of ASM 89 
mass (percentage of total biopsy area) in bronchial biopsies derived from a sub-group of 90 
moderate-to-severe eosinophilic asthmatics who had participated in a 50-week single-centre 91 
(University of Leicester), randomized, double-blind, parallel-group, placebo-controlled trial of 92 
the anti-interleukin (IL)-5 neutralizing antibody mepolizumab (12). Although the sample size 93 
was small, in contrast to fevipiprant, we observed no significant effect of mepolizumab on 94 
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ASM mass (absolute ASM mass percentage increase post-mepolizumab 2.9 ± 4.0%, n=7 versus 95 
placebo 1.5 ± 2.2%, n=5) (mean difference [95% CI] 1.4 [-9.9 to 12.7] %; p=0.79). For these 96 
and other data, see Data File S1. 97 
 98 
An agent-based computational model recapitulates the features of airway remodeling 99 
observed in asthma 100 
To interrogate the mechanisms governing the pathogenesis of asthma, we developed an agent-101 
based computational model of airway remodeling comprising epithelial, mesenchymal, and 102 
inflammatory parameters. In agent-based modeling, a system is divided into agents (here, 103 
airway cells; table S1) capable of interacting with each other and their environment based on 104 
defined rule-sets (13-15). The initial state of the model is illustrated in Fig. S1. Our model 105 
considered interactions between epithelial (columnar and goblet cells), mesenchymal 106 
(fibroblast, myofibroblast, and ASM cells), and inflammatory (eosinophil) cell types. The 107 
various cell types, depending on their phenotype, displayed behaviours ranging from 108 
proliferation, migration, (de)differentiation, apoptosis, and synthesis of extracellular matrix 109 
(ECM) proteins and cytokines (table S1). These virtual cells were simulated within a Strahler 110 
Order 3 virtual airway with a lumen diameter of 1.21 mm and wall area of 1.79 mm2. The 111 
number of each cell type within the model was based on geometrical constraints and published 112 
data. The rule-set governing agent behaviours and interactions was derived from existing in 113 
vitro, animal, and clinical studies (table 1). The underpinning agent interactions and rule-sets 114 
attributed to the agents are summarized in table 1 and represented schematically in Fig. S2.  115 
 116 
In the model, we initially damaged the epithelium to cause 50% epithelial denudation. We then 117 
simulated the consequent normal injury repair and pathological airway remodeling over 180 118 
days by introducing alterations to model parameters (tables S2  S4). The following 119 
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pathological markers and value ranges were considered necessary in the model to reflect the 120 
key hallmarks of severe asthma (1, 2): eosinophilic inflammation (eosinophils/mm2 sub-121 
mucosa) >10; epithelial integrity <70%; and ASM mass  DQG . We conducted 122 
parametric testing by varying, both individually and collectively, parameters from all agent 123 
categories and observing which conditions best captured the above hallmarks of asthma. We 124 
defined the most parsimonious set of parameters to capture these three hallmarks (tables S2  125 
S4). The response to epithelial injury in this model displayed significantly increased 126 
eosinophilic inflammation (p<0.001), ASM mass (p=0.002) and persistent epithelial damage 127 
(p<0.001) compared to the model of healthy control individuals over the 180-day time course 128 
(Fig. 2A).  129 
 130 
Computational modeling predicts that a reduction in eosinophil recruitment is not 131 
sufficient to decrease ASM mass  132 
In order to predict the impact of reducing eosinophil number in our model of airway 133 
remodeling, we incorporated pro-apoptotic or anti-recruitment elements into the model. These 134 
variables were chosen to represent the major respective effects of neutralizing IL-5 (12, 26), 135 
an obligate cytokine for eosinophil survival and maturation, and of blocking activation of DP2, 136 
which promotes eosinophil recruitment (4). We tested an increasing range of intervention doses 137 
and found they resulted in a progressive reduction in airway eosinophilia and ASM mass in our 138 
model of airway remodeling (Fig. 2B, C).  139 
 140 
We then used our computational model of a remodeled asthmatic airway to determine the 141 
predicted percentage increase in eosinophil apoptosis and percentage reduction in eosinophil 142 
recruitment required to reduce the number of bronchial wall eosinophils to that seen in vivo in 143 
clinical trials of mepolizumab (27) and fevipiprant (4), which reduced the eosinophil count in 144 
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patients by 55% and 80%, respectively compared to placebo control. To attain the reduction in 145 
airway eosinophil number clinically observed with mepolizumab, the model predicted that 146 
15% of the eosinophil population must be induced to undergo apoptosis (reduction in airway 147 
eosinophilia versus control of 54.1 ± 4.1 %; Fig. 2B, chequered bar). To attain the reduction in 148 
airway eosinophil number clinically observed for fevipiprant, the model predicted that a 40% 149 
reduction in eosinophil recruitment was required (reduction in airway eosinophilia versus 150 
control of 81 ± 0.6 %; Fig. 2B, hatched bar).  151 
 152 
We subsequently used the pro-apoptotic (15%) and anti-recruitment (40%) models resulting in 153 
a reduction in eosinophil number equivalent to that seen in the mepolizumab and fevipiprant 154 
clinical trials to predict the impact of each intervention on ASM mass. When assuming an 155 
increase in eosinophil apoptosis of 15%, the pro-apoptosis model predicted a small mean ± 156 
SEM decrease in ASM mass (absolute reduction 4.0 ± 0.6%; relative reduction 12 ± 2% versus 157 
control; Fig. 2C, chequered bar). This is consistent with the mepolizumab clinical trial (12) in 158 
which no significant change in ASM mass was observed. When assuming a decrease in 159 
eosinophil recruitment of 40%, the anti-recruitment model predicted a modest reduction in 160 
ASM mass (absolute reduction 8.1 ± 0.5%; relative reduction 25 ± 1% versus control; Fig. 2C, 161 
hatched bar), which was not sufficient to result in the observed response to fevipiprant (13% 162 
absolute and 44% relative reduction in ASM mass). The model therefore suggested the 163 
existence of additional mechanisms that, along with a reduction in airway eosinophilia, 164 
mediated the reduction in ASM mass following treatment with fevipiprant.  165 
 166 
The ASM PGD2/DP2 axis mediates ASM migration 167 
To explore the mechanism by which DP2 antagonism resulted in a decrease in ASM mass, we 168 
assessed the expression and function of DP2 in ASM. We found that DP2 was expressed in the 169 
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ASM-bundle in bronchial biopsies from patients recruited for research bronchoscopies (Fig. 170 
3A), in line with the previous finding that PGD2 primes migration of ASM cells towards 171 
platelet-derived growth factor via DP2 (28). However, DP2 expression was not significantly 172 
different between subjects with severe asthma (60 ± 1; n=8) and healthy controls (57 ± 5; n=11) 173 
(mean difference [95% CI] 2.6 [-9.9 to 15.0]; p=0.67). We also confirmed DP2 expression in 174 
primary human ASM cells at the mRNA (Fig. 3B) and protein levels (Fig. 3 C, D and Fig. S3).   175 
 176 
PGD2 can activate PGD2 type 1 (DP1), DP2 and thromboxane (TP) receptors (9). Therefore, we 177 
investigated the effect of the selective DP2 agonist 13,14-Dihydro-15-keto-PGD2 (DK-PGD2) 178 
and selective DP2 antagonists (fevipiprant, CAY10471 and OC000459) on DP2 receptor 179 
activation, phenotype and behaviour of primary human ASM cells. DK-PGD2 (10-100nM) 180 
stimulated a small but significant increase in filamentous actin (F-actin) polymerisation and 181 
intracellular calcium elevation (Fig. 3 E-F, area under curve of the dose response [AUC DR] 182 
p=0.01 and p=0.002, respectively). Although this did not translate to an effect of DK-PGD2 on 183 
ASM cell migration in vitro (Fig. 4A), blocking activation of DP2 by endogenous PGD2 with 184 
the DP2 antagonist fevipiprant significantly inhibited ASM cell migration in vitro at the highest 185 
drug concentrations (percentage reduction in cells migrating into the wound after 24h vs 186 
vehicle control: 10 nM, 8.8 ± 7.8, p=0.294; 50 nM, 7.7 ± 7.4, p=0.332; 100 nM, 12.8 ± 4.9, 187 
p=0.034, 500 nM, 17.4 ± 6.6, p=0.034; Fig. 4A). We confirmed this effect using other DP2 188 
antagonists including CAY10471 (percentage reduction in cells migrating into the wound after 189 
24h vs vehicle control: 10 nM, 11.6 ± 2.2, p=0.010; 50 nM, 9.3 ± 3.7, p=0.038; 100 nM, 13.6 190 
± 4.4, p=0.027; Fig. 4A), and OC000459 (percentage reduction in cells migrating into the 191 
wound after 24h vs vehicle control: 10 nM, 8.4 ± 3.3, p=0.043; 50 nM, 6.7 ± 4.2, p=0.157; 100 192 
nM, 8.8 ± 1.9, p=0.003, Fig. 4A). Representative photomicrographs of primary ASM 193 
monolayer cultures wounded by scratching followed by incubation with different treatments 194 
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for 24h are shown in Fig. 4B. Thus, we hypothesized that PGD2 was released into the 195 
extracellular milieu by ASM cells to affect ASM behaviour in an autocrine manner. Indeed, 196 
genes involved in PGD2 biosynthesis and metabolism, including PGD2 synthase, were 197 
expressed by ASM cells from subjects with and without asthma (tables S5 and S6). Consistent 198 
with previous reports (29), PGD2 was released by ASM, albeit at a low concentration compared 199 
with mast cells (30-31), and this PGD2 release increased following wounding (129 ± 18 versus 200 
176 ± 22 pg PGD2/ml/10
5 ASM, mean difference [95% CI] 52.0 [4.8 to 99.2]; p=0.02, Fig. 201 
4C). In addition to myofibroblasts, we demonstrated that the ASM progenitor fibrocytes 202 
expressed DP2 (Fig. 4D). The correlation between the change in ASM percentage observed in 203 
those treated with fevipiprant or placebo and the change in lamina propria myofibroblast or 204 
fibrocyte number supported the view that the effects of fevipiprant on ASM mass and lamina 205 
propria mesenchymal cells may have occurred in parallel (Fig. 4E, F). These findings suggested 206 
that anti-DP2 might, in part, reduce ASM mass via a direct and concomitant effect upon ASM 207 
and myofibroblast or fibrocyte recruitment to the ASM bundle. 208 
 209 
The effects on ASM cell migration were not due to cytotoxic effects on the ASM cells as there 210 
was no effect on cell number following treatment for 24h with DK-PGD2 (100 nM), fevipiprant 211 
(500 nM), CAY10471 (100 nM) or OC000459 (100 nM) (Fig. S4A). DK-PGD2 (100 nM), 212 
fevipiprant (500 nM) and CAY10471 (100 nM) had no effect on apoptosis or necrosis (Fig. 213 
S4B). This was supported by a lack of effect of DK-PGD2 (100 nM), fevipiprant (500 nM) or 214 
CAY10471 (100 nM) on cell size or granularity, which are known to change during 215 
apoptosis/necrosis (Fig. S4C-D). Furthermore, DK-PGD2 (10 - 100 nM, Fig. S5A), CAY10471 216 
(10 - 100 nM, Fig. S5B) and fevipiprant (10 - 500 nM, Fig. S5C) neither induced proliferation 217 
of ASM in the presence of serum-free media nor inhibited the ASM cell proliferation induced 218 
by fetal bovine serum (FBS) over 3 days, as assessed by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-219 
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carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium inner salt (MTS) assay and 220 
carboxyfluorescein succinimidyl ester (CFSE) fluorescence (Fig. S5D, E). In the fevipiprant 221 
clinical trial, there was no change in proliferating cell nuclear antigen (PCNA) staining in 222 
bronchial biopsies pre- versus post- fevipiprant treatment or placebo after 12 weeks of 223 
treatment. Additionally, DK-PGD2 (10  100 nM), fevipiprant (10-500 nM) or CAY10471 (10-224 
Q0KDGQRHIIHFWRQ$60Į-smooth muscle actin (SMA) expression (Fig. S6A). This was 225 
supported by a lack of effect of DK-PGD2 (100 nM), fevipiprant (500 nM) or CAY10471 (100 226 
nM) on basal or bradykinin (BK)-stimulated ASM contraction (Fig. S6B-C).  227 
 228 
Modeling predicts that reductions in myofibroblast and eosinophil recruitment are 229 
required for fevipiprant to decrease ASM mass 230 
To support our in vitro findings, we reduced the myofibroblast recruitment (0-50%) in the 231 
computational model together with the 40% reduction in eosinophil recruitment required to 232 
reflect the observed reduction in bronchial biopsy eosinophils after fevipiprant treatment in 233 
patients with asthma as described above. The resulting model predicted that a 50% reduction 234 
in myofibroblast recruitment in concert with reduced eosinophil recruitment would result in a 235 
decrease in ASM mass equivalent to that seen after fevipiprant treatment (cross hatched bars, 236 
Fig. 4G). In contrast, a reduction in myofibroblast recruitment alone was predicted to result in 237 
minimal effects on ASM mass (1.8 ± 1.2% relative reduction). A comparison of the 238 
computational model and fevipiprant trial findings is summarised in Fig. S7.  239 
 240 
Discussion 241 
We report that a drug intervention in asthma, namely fevipiprant (a DP2 antagonist), reduced 242 
ASM mass in bronchial biopsies from asthma patients who had participated in a previous 243 
randomized placebo-controlled trial (4). This is in contrast to the lack of an effect on ASM 244 
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mass in response to mepolizumab that we report here, corticosteroids or the anti-IL-13 245 
monoconal antibody tralokinumab (3, 32, 33). Our computational model and in vitro work 246 
supported the view that the reduction in ASM mass in response to fevipiprant was a 247 
consequence of inhibiting eosinophilic inflammation in concert with a direct reduction in the 248 
recruitment of myofibroblasts to the ASM-bundle. Thus, fevipiprant may be a potential therapy 249 
to target airway remodeling in asthma and its clinical benefits observed previously could be in 250 
part due to its effects upon ASM.    251 
  252 
One limitation of our study is that the number of paired biopsies collected in the fevipiprant 253 
trial included modest numbers of subjects despite the trial being one of the largest biopsy 254 
studies undertaken in subjects with asthma. Therefore, it is important to extend and confirm 255 
these findings in future studies. Likewise, it is possible that the lack of effect observed with 256 
other anti-inflammatory interventions is due to lack of statistical power conferred by the small 257 
sample sizes. However, our computational model data suggest that these anti-inflammatory 258 
approaches are unlikely to be effective unless they have additional direct effects upon ASM. 259 
Indeed, a small reduction in ASM mass was previously reported following treatment with the 260 
calcium channel blocker gallopamil, which had been proposed to have direct effects upon ASM 261 
activation, but the reduction in ASM mass was no different from placebo (34).  262 
 263 
Another limitation of our study is that we cannot completely exclude the possibility that the 264 
effect of fevipiprant upon ASM mass both in vivo and in vitro is an off-target effect. However, 265 
we used 3 selective and specific DP2 antagonists, including fevipiprant, for the in vitro 266 
experiments, and therefore we consider it unlikely that the findings we report on ASM 267 
activation and migration are due to off-target effects. Our in vitro findings also imply that the 268 
major effect of DP2 antagonism upon ASM function was the inhibition of migration of ASM 269 
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progenitors to the airway, either from the blood or via attenuation of epithelial-mesenchymal 270 
transition, rather than through effects on proliferation or apoptosis. This is consistent with the 271 
concept that mesenchymal cells exhibit plasticity in phenotype (35). In keeping with our in 272 
vitro observations, we did not identify any changes in PCNA staining in the ASM bundle in 273 
vivo, suggesting there was no active proliferation of ASM. Taken together, these results 274 
suggest that neither proliferation nor apoptosis contribute to the effects of DP2 antagonism 275 
upon ASM mass, although we cannot completely exclude some contribution from these 276 
processes. 277 
 278 
A strength of our study is the integration of findings from in vivo clinical trials and in vitro and 279 
computational models. We developed a comprehensive agent-based model of airway 280 
remodeling during asthma. Previous computational approaches have been applied to uncover 281 
mechanisms driving unresolved allergic inflammation and airway hyper-responsiveness in 282 
asthma (15, 36), but not airway remodeling. Our agent-based model was created to represent 283 
the airway in 3-dimensions. A possible limitation is that our model was utilized for one layer 284 
of agents and simulated a distal airway to balance model resolution and computational 285 
complexity. However, we believe our model is representative as it captures the features of the 286 
normal and pathological workings of the entire airway. Specifically, our computational model 287 
displayed features consistent with moderate-to-severe asthma including damaged bronchial 288 
epithelium, eosinophilic inflammation and increased ASM mass. This model responded to 289 
perturbations reflective of changes in eosinophil survival and trafficking and provided new 290 
insights into possible mechanisms of action of DP2 antagonists versus anti-IL5 upon airway 291 
remodeling. This model has also given us insights into the effects of DP2 antagonism, which 292 
would not be possible in vitro due to the limitations of studying multiple cell-cell interactions 293 
within a complex airway structure. Although our computational model is not patient-specific 294 
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it represents an average patient with asthma and airway remodeling. This virtual patient 295 
represents a step towards patient-specific modeling in respiratory medicine. We anticipate our 296 
integrated approach combining agent-based modeling with in vivo clinical data and in vitro 297 
findings will provide further insights into asthma in future studies.  298 
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Materials and methods 299 
Study design  300 
The objective of the study was to use an integrated strategy encompassing samples from a 301 
randomized placebo-controlled trial in asthma patients evaluating fevipiprant (DP2 antagonist) 302 
and mepolizumab (anti-interleukin-5 antibody), in vitro experiments, and predictive 303 
computational agent-based models simulating asthma pathogenesis to investigate the impact of 304 
DP2 antagonism upon ASM mass and determine the mechanisms driving this effect.  305 
 306 
Subjects with persistent moderate-to-severe asthma and an elevated sputum eosinophil count 307 
(n=61) participated in a single-centre (University of Leicester) randomized placebo-controlled 308 
trial of the DP2 antagonist fevipiprant (225mg twice per day orally) in addition to standard of 309 
care (4). In an independent study, subjects (n=61) who had refractory eosinophilic asthma 310 
participated in a single-centre (University of Leicester), randomized placebo-controlled trial of 311 
an anti-interleukin-5 neutralising antibody mepolizumab (750 mg intravenous infusions every 312 
4 weeks over 50 weeks) in addition to standard of care (12). A subgroup of subjects underwent 313 
bronchoscopy and bronchial biopsy in each independent study before and after administration 314 
of drug or placebo. The studies were approved by the Leicester and Northamptonshire ethics 315 
committee (05/Q2502/98 and 11/EM/0402, respectively) and registered with 316 
ClinicalTrials.gov (ISRCTN75169762, NCT01545726 and with EudraCT, number 2011-317 
004966-13). The studies were carried out in accordance with CONSORT guidelines (4, 12). 318 
 319 
The sample size for the fevipiprant and mepolizumab randomized controlled trials were 320 
determined based on change in the sputum eosinophil count as the primary outcome as 321 
described in Gonem et al (4) and on the number of exacerbations of asthma per subject as the 322 
primary outcome as described in Haldar et al (12). Assessing change in airway smooth muscle 323 
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mass was in the pre-specified exploratory analysis plan for the fevipiprant clinical trial, and 324 
was performed post-hoc for mepolizumab. The inclusion and exclusion criteria for the 325 
fevipiprant and mepolizumab trials, randomisation and blinding procedures are described in 326 
Gonem et al (4) and Haldar et al (12), respectively. For the in vitro experiments the observers 327 
analysed the experiment blinded to conditions. 328 
 329 
Additional asthmatic subjects and healthy controls were recruited from a single-centre 330 
(University of Leicester) for research bronchoscopies from which tissue sections and primary 331 
ASM cells could be derived. Those with asthma gave an appropriate history and had objective 332 
evidence of variable airflow obstruction or airway hyper-responsiveness, as described 333 
previously (37). Healthy controls had no history of asthma and possessed normal lung function. 334 
The study was approved by the Leicestershire and Northamptonshire Ethics Committee 335 
(08/H0406/189).  336 
 337 
Immunohistochemistry 338 
To determine DP2 expression by ASM, bronchial biopsies from healthy controls (n=11 donors) 339 
and asthmatic subjects (n=8 donors) were embedded in glycomethacrylate (GMA) (11). For 340 
each subject, sequential 2 µm sections were cut and stained using polyclonal  anti-DP2 antibody 341 
(Thermo-Fisher Scientific) or rabbit immunoglobulin (Ig) G isotype control (Immunostep), and 342 
DQĮ-SMA antibody (clone 1A4, Dako) or mouse IgG2a isotype control (clone DAK-GO5, 343 
Dako). Antibody binding was detected using the EnVision FLEX kit (Dako). For determining 344 
ASM mass pre- and post-treatment with fevipiprant (n=14) or placebo (n=13), and pre- and 345 
post-treatment with mepolizumab (n=7) or placebo (n=5) bronchial biopsies from asthmatic 346 
subjects were embedded in GMA and stained for Į-SMA as above. ASM mass was determined 347 
as the percentage of the total assessable biopsy area as previously described by a single 348 
16 
 
observer (RB). Repeatability of ASM mass assessment was tested and was excellent within 349 
and between observers with intraclass correlations of 0.95 and 0.96 respectively. 350 
Myofibroblasts were identified as Į-SMA positive stained cells in the lamina propria that were 351 
neither located as part of the ASM-bundle nor as vascular smooth muscle cells adjacent to 352 
vessels per mm2 of submucosa. To identify fibrocytes in bronchial biopsies pre- and post- 353 
fevipiprant (n=12) or placebo (n=13), for each subject sequential 2 µm sections were cut and 354 
stained using an mouse monoclonal anti-cluster of differentiation (CD) 34 antibody (Dako) or 355 
mouse IgG1 isotype control (Dako) and Į-SMA as above. Fibrocytes were identified as the 356 
subset of Į-SMA positive cells/mm2 lamina propria that also stained positive for CD34 in 357 
sequential sections. The intensity of DP2 stain was quantified as reciprocal intensity (38) on a 358 
scale out of 250, assessed by a single observer. Assessors were blind to clinical characteristics, 359 
treatment allocation and order of bronchial biopsy in the clinical trial.  360 
 361 
Cell culture 362 
ASM bundles were isolated from bronchial biopsies (n=27 asthmatic, 2 non-asthmatic) and 363 
lung resection material (n=4, non-asthmatic). The clinical characteristics of subjects that 364 
underwent bronchoscopy to provide primary ASM cultures are as shown (table S5). Primary 365 
ASM cells were cultured in DMEM with Glutamax-1 supplemented with 10% FBS, 100U/mL 366 
penicillin, 100Pg/mL streptomycin, 0.25 Pg/mL amphotericin, 100 PM non-essential amino-367 
acids, and 1 mM sodium pyruvate (Gibco). Cells were characterized IRUĮ-SMA expression 368 
using a mouse monoclonal anti-Į-SMA antibody (clone 1A4, Dako) or mouse IgG2a isotype 369 
control (clone DAK-GO5, Dako) by flow cytometry and used between passage 2-6.  370 
 371 
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Fibrocytes (n=6) were isolated from peripheral blood mononuclear cells as described 372 
previously (39). PBMCs were washed twice with HBSS and cultured in tissue culture flasks 373 
coated with 40 µg/ml fibronectin for 5 -10 days prior to experimentation. 374 
 375 
Prior to experimentation ASM cells from each individual donor were incubated in media in the 376 
presence of a selective DP2 agonist (DK-PGD2, Cayman Chemical Company (40)) or selective 377 
DP2 antagonists (CAY10471, OC000459 and fevipiprant, Cayman Chemical Company and 378 
Novartis (41-43) vs appropriate vehicle controls (Dimethyl sulfoxide (DMSO) for DK-PGD2, 379 
CAY10471 and OC000459, and 10% dH20 in DMSO for fevipiprant). 380 
 381 
Wound healing assay 382 
ASM cells from individual donors were seeded onto 6 well plates coated with 10 µg/ml 383 
fibronectin at a density of 2×105 cells and allowed to adhere and reach 90-100% confluence. 384 
Cells were then serum deprived for 24h. Cells were wounded by scratching using a sterile 200 385 
µl pipette tip in a predetermined grid pattern (44). Following wounding ASM cells were 386 
washed x4 with serum free media prior to addition of serum free media with DK-PGD2 (10-387 
100 nM), fevipiprant (10-500 nM), CAY10471 (10-100 nM) or OC000459 (10-100 nM) or 388 
vehicle control for 24 h. Photographs of 4 different wounded areas per condition were then 389 
photographed at baseline and after 24h using an EVOS xl core cell imaging system (Thermo 390 
Fisher Scientific), and the outline of the wound at time zero transposed onto the corresponding 391 
24h photograph. The number of cells that had moved into the wounds were analysed by a 392 
blinded observer. 393 
 394 
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Computational model approach and framework 395 
The computational model capturing airway remodeling was developed via the agent-oriented 396 
approach (13), which charts the spatiotemporal evolution of a system as a result of flexible, 397 
high-level interactions between agents as well as agents and their environment (14). The 398 
Flexible Large-scale Agent-based Modelling Environment (www.flame.ac.uk), an agent-based 399 
platform employing stream communicating X-machines (45) as agents, was utilized to develop 400 
the model.  401 
 402 
The baseline model and computational iterations 403 
Based on the agents, set of rules, and initial conditions (table 1, table S1, Fig. S1, Fig. S2, 404 
supplementary materials) a baseline model of airway remodeling, comprising epithelial, 405 
mesenchymal, and inflammatory parameters, was developed that captures trends observed 406 
during normal airway remodeling, and additionally following introduction of abnormal levels 407 
of variation within model parameters  leads to the emergence of patterns observed during 408 
pathological remodeling and, as such, the key hallmarks of asthma  this approach is referred 409 
to as pattern-oriented modelling (13). After review of clinical literature, the following clinical 410 
markers were considered to appropriately reflect the key hallmarks of asthma: i) eosinophilic 411 
inflammation (defined as eosinophils/mm2 submucosal area) >10 (5, 11, 46), ii) epithelial 412 
integrity <70% (4-5, 47-50) and iii) airway muscle mass/wall area DQG-5, 47, 413 
49).  414 
 415 
The model starts by assessing the epithelial integrity, the number and location of inflammatory 416 
cells (both the universal inflammatory cells and eosinophils), and the status of muscle cells. 417 
Remodeling is initiated in case of a compromised epithelium or increased inflammation within 418 
the system, resulting in a cascade of events, which, depending on the relevant boundary 419 
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conditions, lead to further inflammation, fibrosis, goblet cell hyperplasia, recruitment of 420 
muscle, and increased collagen deposition. Furthermore, remodeling, could be exacerbated or 421 
prolonged by the nature of initial or secondary conditions assigned to the computation.  422 
 423 
More specifically, a normal or healthy set of conditions triggered remodeling in the absence 424 
of an intact epithelium (or a challenge that resulted in epithelial denudation) by initiating 425 
fibrosis and recruiting the universal inflammatory cell. The inflammatory cell further released 426 
pro-inflammatory cytokines to recruit eosinophils and muscle  the latter was accounted for in 427 
the model by the differentiation of fibroblasts into myofibroblasts. The eosinophils, moreover, 428 
caused further damage by degranulating and releasing cytotoxic proteins, which, if close to the 429 
epithelium, resulted in necrosis of the epithelial cells  thereby, prolonging remodeling. We 430 
worked with the hypothesis that any set of conditions that perpetuate these interactions will 431 
result in pathological remodeling, thereby capturing the hallmarks of asthma. The various 432 
parameters and their quantitative values, derived from existing literature, have been, along with 433 
the relevant references, listed in table 1, with a schematic interlinking the various elements of 434 
the model shown in Fig. S2. 435 
 436 
While the model does not explicitly consider cytokine activity, i.e. their release, diffusion, and 437 
half-life, it implicitly accounts for it by requiring that those cells impacted by the cytokine 438 
molecules share a localized region with the effector cell. For example, only ASM cells within 439 
close proximity of the universal inflammatory cellswill undergo hypertrophy or contraction, 440 
refer to supplementary material for more details.  441 
 442 
Finally, the simulations progress in a number of time steps, with each time step matching 1 443 
hour of real time. Time intervals of 30 minutes and 2 hours were also tested on the baseline 444 
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case (Case I) and yielded results indistinguishable from simulations conducted with 1-hour 445 
time steps. Thus, we opted for the 1-hour interval to strike a balance between computational 446 
costs and ensuring adequate resolution regarding activities we wished to capture via the model. 447 
The total simulated time for all simulations, including remodeling and intervention, was ~6 448 
months (4350 iterations). This time period allowed investigation of both the short- and long- 449 
term response following either a challenge or intervention. Each model was simulated five 450 
times (n=5) to assess the sensitivity of the model to inherent stochastic elements (such as cell 451 
cycle, new coordinates of the daughter cells and migration of the universal inflammatory cells). 452 
The internal random elements accounted for intra- and inter-cellular biological stochasticity. 453 
Testing model for insensitivity to these random elements also served to provide an indicator 454 
for model precision.  455 
 456 
A detailed description of the model, its development, and its validation is provided in the 457 
supplementary materials. 458 
 459 
Statistical analysis  460 
Statistical analysis was performed using with SAS/STAT software and GraphPad Prism. Data 461 
were tested for normality using the Shapiro-Wilk test. For normally distributed data, two-tailed 462 
paired t-tests, one sample t-tests, or one-way ANOVA were used as appropriate. For non-463 
parametric data, Wilcoxon matched pairs sign ranked test or Kruskal-Wallis tests were used as 464 
appropriate. Correlations were performed using Spearmans correlation. Details of statistical 465 
tests used are provided in figure legends. p < 0.05 was considered statistically significant. 466 
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Category Activity Rules Parameters 
Baseline 
Value 
Comments 
Epithelial 
Migration 
Dedifferentiated epithelial 
cells migrate to repair the 
damaged epithelium, then 
undergo proliferation. 
Migration rate 5 µm/h Migration rate was consistent with in vitro studies (16-18). 
Migration delay 5h 
Dedifferentiated cells migrate after 5h; doubled to 10 h to represent slowly recovering 
epithelium. 
Differentiation 
Cells at the edge 
dedifferentiate into a 
flattened phenotype. 
Dedifferentiation 
probability 
50% 
A 50% probability per iteration was applied to determine whether an epithelial cell 
dedifferentiates. This was altered to 5% per iteration for the defective epithelium. 
Delay in 
proliferation 
2-8 h 
Edge cells require 2-8h to flatten out (16); this was increased by 3X (624h) for slow 
epithelial recovery. 
Proliferation 
Dedifferentiated epithelial 
cells proliferate following 
their migration to the 
opposite edge of a 
compromised epithelium. 
Ciliated:Goblet 
ratio 
0.7:0.3 
& 0.1:0.9 
The number of goblet cells increase by 23X in severe asthma (19-22) given the 
inflammation status in disease. The probability of differentiating to a ciliated: goblet cell fate 
was either 0.7:0.3 (less inflamed) or 0.1:0.9 (more inflamed). 
Apoptosis 
This feature was not 
included in the baseline 
model. 
Auto-
denudation 
N/A 
No apoptosis rate was applied to the baseline model. In mild shedding every 25 h cells 
underwent apoptosis with 50% probability; moderate apoptosis with the probability of 1% 
at each iteration; extreme 10% at each iteration. 
Inflammatory 
Cell migration 
and activation 
Inflammatory cells migrate 
into the airway in response 
to epithelial denudation, and 
their activation promotes 
eosinophil recruitment. 
Frequency of 
recruitment 120 h 
Inflammatory cells were added every 120h to the model with recruitment frequency 
increased to 60h and 50h in disease. 
Inflammatory 
cells recruited 30 
Inflammatory cell number was chosen to reflect previous reports (11) and, in disease, this 
was increased by 1.5-2X (23). 
Eosinophil 
recruitment 
45 
Eosinophil recruitment was triggered by increased inflammatory cell number; 45, based on 
previous reports (11) and in disease this threshold was halved. 
Degranulation 
Inflammatory cell activation 
promotes cell recruitment 
and fibroblast differentiation 
Inflammatory 
cytokine release 
25/ 75/ 
105 h 
The universal inflammatory cell was assigned 150h life; releasing cytokines for 25h (or 75 
and 105h for epithelial integrity of <55% and 30% respectively). In disease, inflammatory 
cell life was reduced to 65, 40, and 25 h (releasing cytokines for 85, 110, and 125h, 
respectively). 
Apoptosis 
Inflammatory cells promote 
eosinophil survival 
Eosinophil life 
in the airway 
10/ 30/ 
45h 
Eosinophils survival is ~10h within a normal airway (24). This was increased to 30 and 45h 
for epithelial integrity of <55% and 30% respectively. In disease, the life of eosinophils was 
doubled to 20, 60, and 90 h. 
Mesenchymal 
Differentiation 
Inflammatory cells promote 
increased ASM mass 
ASM activation 25 cells 
The threshold number of inflammatory cells above which myofibroblast-ASM differentiation 
is induced (11) which was reduced by 50% in disease. 
Differentiation 
Inflammatory cells promote 
fibroblast-myofibroblast 
differentiation 
(Myo)fibroblast 
differentiation 
probability 
30% 
Increased fibroblast differentiation or myofibroblast recruitment in the presence of activated 
inflammatory cells increased to 50% in disease. 
Proliferation 
Fibroblast proliferation 
increased by inflammatory 
and epithelial cells 
Fibroblast 
growth rate 
132 
iterations 
Animal models indicate that lung fibroblasts divide every 5.5 days (132 iterations in model), 
which reduces to 2 days (48 iterations in model) in the animal model of asthma (25). 
Apoptosis 
Myofibroblast survival 
supported by activated 
inflammatory cells 
Myofibroblast 
apoptosis 
5 cells The threshold number of inflammatory cells below which myofibroblast apoptosis was 
induced, which was reduced to 2 in disease. 
 759 
Table 1. Agents, Rules and Model. The computational airway model rule-set, parameters, and 760 
which parameters were altered to observe airway remodeling.  761 
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Figure legends 762 
 763 
Fig. 1. Increased ASM mass in asthma is reduced by fevipiprant. A. Representative 764 
photomicrograph of a bronchial biopsy from a participant with severe asthma in the fevipiprant 765 
(DP2 antagonist) trial, showing increased ASM (brown stained Į-SMA), disrupted epithelium 766 
and lamina propria. B. ASM mass, as measured by percentage Į-SMA positive area, in 767 
bronchial biopsies from asthmatic subjects pre- and 12 weeks post-treatment with fevipiprant 768 
(n=14) or placebo (n=13). A two-tailed paired t-test was used for within group comparisons 769 
(p=0.022 and p=0.522), and a two-tailed unpaired t-test was used to compare the difference in 770 
ASM mass observed following treatment with fevipiprant to that seen in the placebo group 771 
(p=0.034).  772 
 773 
Fig. 2. Computational model-based investigation of interactions between airway 774 
inflammation and ASM mass. A. The mean time course from 6 simulations of the response 775 
to epithelial injury (50% denudation at time zero) over 180 days showing increased eosinophil 776 
numbers, ASM mass and persistent epithelial damage in the model of airway remodelling in 777 
asthma versus resolution of the epithelial injury, eosinophil numbers and persistently low ASM 778 
mass in the healthy control model (p<0.01 for comparisons of each parameter over time 779 
between the patient model versus healthy control model, two-tailed unpaired t-tests). B. 780 
Predicted reduction in eosinophil number over 180 days following reduction in eosinophil 781 
recruitment or increase in eosinophil apoptosis in the computational model (n=5 simulations). 782 
C. Relative change in the ASM mass percentage at 180 days, predicted as a consequence of 783 
results in panel B (n=5 simulations).  784 
 785 
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Fig. 3. ASM cells express functional DP2. A. Representative photomicrograph of DP2 staining 786 
in bronchial biopsies from a subject with severe asthma (inset: isotype control). B. Quantitative 787 
PCR cycle threshold values for expression of ASM DP2 mRNA vs the 18S ribosomal RNA 788 
housekeeping gene RNA18S5, mean DP2 Ct (threshold cycle) [95% CI]: 27.9 [26.1 - 29.8], 789 
n=7. C. Example histogram of DP2 expression (black trace) in ASM cells by flow cytometry 790 
versus isotype control antibody (grey trace);  fold increase in geometric mean fluorescence 791 
intensity (GMFI) of anti-DP2 antibody/isotype control antibody [95% CI]: 1.3 [1.2 - 1.4], n=15 792 
donors, p<0.001, two-tailed paired t-test against isotype control. D. Representative 793 
photomicrographs (x20 magnification) VKRZLQJ $60 Į-SMA expression (green, left hand 794 
panel;isotype control antibody, inset) and ASM DP2 expression (red, right hand panel; isotype 795 
control antibody, inset) by immunofluorescence staining; nuclei are stained with 4',6-796 
diamidino-2-phenylindole (DAPI, blue). E. F-actin polymerisation in primary human ASM 797 
cells (n=9 donors) in response to DK-PGD2
 treatment or Dulbecco's Modified Eagle's Medium 798 
(DMEM) containing 50% FBS as a positive control; geometric mean AUC DK-PGD2 DR [95% 799 
CI]: 46 [25  104] x 102; p=0.01, one sample t-test against a hypothetical value of zero. F. 800 
Intracellular calcium (Ca2+i) elevation in primary human ASM cells (n=6-9 donors) in response 801 
to DK-PGD2
 treatment or ionomycin (1.5 µg/ml) as a positive control; geometric mean AUC 802 
DK-PGD2 DR [95% CI]: 130 [78  230] x 103; p=0.002, one sample t-test against a 803 
hypothetical value of zero. Data are plotted as mean ± sem. Two-tailed paired t-tests were 804 
performed to compare each condition with its vehicle control; * p < 0.05, except FBS where 805 
Wilcoxon matched pairs sign ranked test was used, denoted by ^ p < 0.05.  806 
 807 
Fig. 4. A DP2 antagonist reduces ASM migration and recruitment of myofibroblasts and 808 
fibrocytes. All experiments were carried out in serum-free media. A. Shown are data for the 809 
wound closure after 24h of ASM cells that had been grown in monolayers and then wounded 810 
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by scratching with a pipette tip followed by incubation with different treatments for 24h: DP2 811 
agonist DK-PGD2 (n=4-5 donors), the DP2 antagonists fevipiprant (n=8 donors), CAY10471 812 
(n=6-8 donors) and OC000459 (n=7 donors), or DMEM culture medium containing 10% FBS 813 
as a positive control. Two-tailed paired t-tests were performed to compare each condition with 814 
its vehicle control; * p<0.05 vs vehicle control. Data are expressed as mean ± sem. B. 815 
Representative photographs of  ASM monolayers wounded by scratching with a pipette tip 816 
after 24h (vehicle control for fevipiprant, 500 nM fevipiprant, DMEM containing 10% FBS 817 
control (upper panel); vehicle control for CAY10471 and OC000459, 100 nM CAY10471 and 818 
100 nM OC000459 (lower panel), black lines represent the wound edge at 0h, scale bar = 250 819 
µm. C. PGD2 release by unwounded and wounded ASM cells after 24h; p=0.02, Wilcoxon 820 
matched pairs signed rank test, n=10 donors. Data are expressed as mean ± sem. D. 821 
Representative flow cytometry traces of isotype control antibodies (grey traces) versus Į-SMA 822 
expression (left hand panel, black trace, mean percentage fibrocyte population positive for Į-823 
SMA expression [95% CI]; 97 [93  100] %, n=4 donors) and DP2 expression (right hand panel, 824 
black trace, GMFI fold difference DP2 antibody/isotype control antibody [95% CI]; 1.6 [1.3  825 
2]; p=0.0064, two-tailed paired t-test against isotype control antibody, n=6 donors) by 826 
fibrocytes. E. Correlation between change in myofibroblast number in the lamina propria and 827 
absolute change in ASM mass as a percentage of the total biopsy area (fevipiprant: black circle, 828 
n=14, placebo: black triangle, n=13), Spearman r [95% CI]: r=0.347 [-0.050-0.649]; p=0.076. 829 
F. Correlation between change in fibrocyte number in the lamina propria and absolute change 830 
in ASM mass as a percentage of the total biopsy area (fevipiprant: black circle, n=12, placebo: 831 
black triangle, n=13), Spearman r [95% CI]: r=0.538 [0.169-0.774]; p=0.006. G. Predicted 832 
relative reduction in percent ASM mass at 180 days in the computational model as a 833 
consequence of reduced myofibroblast recruitment (30-50%) in combination with a 40% 834 
reduction in eosinophil recruitment in the computational model (n=5 simulations). 835 
